Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice

Br J Clin Pharmacol. 2018 Mar;84(3):477-481. doi: 10.1111/bcp.13462. Epub 2017 Dec 6.

Abstract

Adherence is pivotal but challenging in ulcerative colitis (UC) treatment. Many methods to assess adherence are subjective or have limitations. (Nac-)5-aminosalicylic acid (5-ASA) urinalysis by high-performance liquid chromatography (HPLC) seems feasible and reproducible in healthy volunteers. We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care. Twenty-nine patients (51.7% male, mean age 52 ± 11 years) were included (median FU 9 months) and weekly spot urine samples were collected. We found large variation in spot (Nac-)5-ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5-ASA. In conclusion, spot (Nac-)5-ASA urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.

Keywords: HPLC; MMX-mesalazine; adherence; compliance; inflammatory bowel disease.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*
  • Anti-Inflammatory Agents, Non-Steroidal / urine
  • Chromatography, High Pressure Liquid / methods
  • Colitis, Ulcerative / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Medication Adherence*
  • Mesalamine / administration & dosage*
  • Mesalamine / urine
  • Middle Aged
  • Prospective Studies
  • Urinalysis / methods
  • Young Adult

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine